Sign In
Buy DYAI
$1.05
-0.0200 (-1.87%)
At Close: Jul 31, 2026
Dyadic Reports 2024 Year-End Financial Results and Business Updates
04:05pm, Wednesday, 26'th Mar 2025
JUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
04:00pm, Wednesday, 12'th Mar 2025
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the
Dyadic to Attend Multiple Industry Events in March
08:30am, Thursday, 06'th Mar 2025
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 06'th Jan 2025
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the e
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
08:30am, Thursday, 21'st Nov 2024
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therape
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
08:16pm, Saturday, 16'th Nov 2024
Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President & CEO Joseph Hazelton - COO Pat
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
04:30pm, Monday, 04'th Nov 2024
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the e
Dyadic Expands Global Presence with Participation in Key Industry Events
08:00am, Wednesday, 09'th Oct 2024
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufactur
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
09:50am, Monday, 23'rd Sep 2024
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the
Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript
11:05pm, Tuesday, 13'th Aug 2024
Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President and CEO Joseph Hazelton - COO Pat
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
04:00pm, Tuesday, 30'th Jul 2024
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the e
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership w
Dyadic to Attend Industry Events in June
04:30pm, Thursday, 30'th May 2024
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture
Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
10:15pm, Friday, 17'th May 2024
Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Mark Emalfarb - President & CEO Ping Rawson - CFO Joseph Hazelton - COO Conferen
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
04:00pm, Tuesday, 14'th May 2024
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor bi
